The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CARsgen Therapeutics Inc’s investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cells (CT053) for the treatment of multiple myeloma.
